Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Open-Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies or Have Recently Transitioned From Systemic Therapies

NCT00338143 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00338143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00338143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Open-Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies or Have Recently Transitioned From Systemic Therapies
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2003
Completion date
May 31, 2004
Enrollment
1,200
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis